December 2025 in “Journal of Dermatological Treatment” GT20029 helps regrow hair in men with hair loss and is well-tolerated.
January 2021 in “Journal of clinical & experimental dermatology research” The new 5% minoxidil formulation without propylene glycol effectively promotes hair growth with fewer side effects and better user satisfaction.
27 citations
,
February 2017 in “Clinical, Cosmetic and Investigational Dermatology” New compounds were found to help increase hair growth and decrease hair loss.
1 citations
,
February 2025 in “International Journal For Multidisciplinary Research” A new accurate method was developed to measure Minoxidil and Aminexil in solutions.
March 2014 in “Journal of The American Academy of Dermatology” The new topical product combined with finasteride significantly increased hair thickness without side effects.
January 2020 in “International Journal of Herbal Medicine” The freeze-dried hair growth product is more stable and pure than the natural form.
1 citations
,
June 2021 in “International journal of pharmaceutical compounding” Minoxidil in FOAMIL is stable for at least 180 days at various concentrations.
2 citations
,
May 2024 in “International Journal of Medical Arts” Diphenylcyclopropenone (DPCP) is more effective than anthralin for treating resistant alopecia areata.
1 citations
,
January 2014 The emulgel formulation F6 released more Minoxidil than the gel formulation F1.
July 2024 in “Forum Dermatologicum” Topical treatments for hair loss can be effective but need careful safety evaluation.
3 citations
,
July 1988 in “International Journal of Dermatology” Minoxidil is safe and effective for treating early male pattern baldness.
5 citations
,
January 2011 in “Der Pharmacia Lettre” The method accurately measures Finasteride and Tamsulosin in tablets without interference.
February 2024 in “Journal of Molecular Structure” The new minoxidil and salicylic acid hydrogel improves alopecia treatment.
2 citations
,
November 2017 in “Food Additives & Contaminants: Part A” The new method accurately detects illegal hair-growth drugs in dietary supplements.
April 2016 in “Plastic and reconstructive surgery. Global open” Tafluprost could be a potential treatment for hair loss by promoting hair growth phase changes.
10 citations
,
December 2014 in “Journal of Pharmaceutical and Biomedical Analysis” Finasteride's polymorphic form affects capsule quality and drug effect, requiring strict control.
April 2020 in “Dermatology and therapy” New 5% minoxidil solution improves scalp hydration, reduces redness, and may be safer for sensitive users.
4 citations
,
February 2019 in “PubMed” Clascoterone may be an effective topical treatment for hair loss.
50 citations
,
July 2014 in “International Journal of Clinical Pharmacology and Therapeutics” New finasteride solution effectively reduces baldness-causing hormone, potentially with fewer side effects.
11 citations
,
May 2010 in “Journal of Medicinal Chemistry” A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.
February 2024 in “Current Drug Delivery” The new minoxidil emulgel with marine-based polymers shows effective controlled drug release for hair growth treatment.
August 2025 in “International Journal of Pharmaceutics” A new finasteride treatment may quickly and effectively promote hair regrowth.
October 2020 in “Journal of Pharmaceutical Sciences” Topical finasteride with EGCG or TA improves drug release and dermal uptake, potentially treating hair loss effectively.
June 2020 in “Acta medica Philippina” Topical adenosine may effectively and safely treat hair loss.
June 2025 in “British Journal of Dermatology” Tofacitinib is more effective than methotrexate for treating moderate-to-severe alopecia areata.
November 2022 in “Nihon Nyuusankin Gakkaishi/Nihon Nyūsankin Gakkaishi” The lotion with N793 strain significantly increased hair density and reduced hair loss safely.
June 2025 in “British Journal of Dermatology” Tofacitinib was more effective than methotrexate for treating alopecia areata.
November 2020 in “International journal of pharmaceutical compounding” A stable and simple finasteride suspension was developed that retains over 94.3% of its concentration for up to 90 days and doesn't significantly increase occupational exposure, but safety measures are still advised.